Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Mary Crowley Cancer Research Center, Dallas, TX, United States



Survival: 7.6 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Dallas, TX
   
Hospital: Mary Crowley Cancer Research Center
   
Journal: Link
   
Date: 7/2009

Description:
Patients:
There were 74 patients with metastatic melanoma involved in this Phase II trial. Of these, 50 (67.6%) were male. The median patient age was 58 years old, with a range of 27-79.

Treatments:
Patients were given a combination of two chemotherapeutic drugs, cisplatin and talabostat. Talabostat is an agent that stimulates the immune system to kill cancer cells.

Toxicity:
During this study, 39 (52.7%) patients died, the majority of these deaths (36 of 39) resulting from progressive disease. In addition, adverse events of Grade 3 or higher were experienced by 56.8% of patients. These effects included anemia, thrombocytopenia, neutropenia, and tinnitus (ringing in the ears).

Results:
The median overall survival in this study was 7.6 months.

Support:
Two of the authors are employed by Point Therapeutics, Inc., makers of talabostat.

Correspondence: Dr. John Nemunaitis

E-mail to a Friend Email Physician More Information